Skip to main content
main-content

08.03.2017 | Original Article – Clinical Oncology | Ausgabe 7/2017

Journal of Cancer Research and Clinical Oncology 7/2017

Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia

Zeitschrift:
Journal of Cancer Research and Clinical Oncology > Ausgabe 7/2017
Autoren:
Verena S. Hoffmann, Joerg Hasford, Michael Deininger, Jorge Cortes, Michele Baccarani, Rüdiger Hehlmann
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00432-017-2385-7) contains supplementary material, which is available to authorized users.

Abstract

Purpose

Most randomized clinical trials evaluating second generation tyrosine kinase inhibitors (TKI) for the first-line treatment of Chronic Myeloid Leukemia used as comparator the ‘standard’ dose of 400 mg imatinib daily. Several studies showed higher rates of major molecular remission (MMR) at 12 months with 800 mg compared to 400 mg, suggesting that high-dose imatinib may be the appropriate comparator rather than 400 mg.

Methods

We systematically reviewed randomized trials comparing the two dosages, calculated a common estimator and compared the result to a common estimator of trials evaluating a second generation TKI in comparison with 400 mg imatinib daily.

Results

We identified three trials comparing 400–800 mg imatinib resulting in a common relative risk of 1.30 (1.13–1.49) and indicating a significantly higher rate of MMR in patients treated with 800 mg imatinib (p = 0.0003). We identified five trials comparing 400 mg imatinib daily to a second generation TKI. The common relative risk for MMR at 12 months was 1.69 (1.50–1.90, p < 0.0001). Differences in the prognostic profiles precluded a direct comparison of the common efficacy estimates.

Conclusions

We conclude that imatinib was probably not licensed at the optimal dose initially. We suggest that in the future, new TKIs are compared with a higher dose of imatinib. In addition, high-dose imatinib should be considered more often for routine clinical decisions based on the characteristics of the individual patient.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt e.Med zum Sonderpreis bestellen!

Sichern Sie sich jetzt Ihr e.Med-Abo und sparen Sie 50 %!

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 7/2017

Journal of Cancer Research and Clinical Oncology 7/2017 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.